In short: Gene therapy changes genetic information – a gene is added, switched off or precisely corrected. Cell therapy gives living cells as a medicine, such as processed immune or stem cells. The two overlap: when cells are genetically modified in the laboratory and then returned, as with CAR-T cells, the EU classifies the product as a gene therapy.
In the EU, gene and cell therapies belong to the “advanced therapy medicinal products” (ATMPs). They are authorised centrally by the European Medicines Agency and are usually given only in specialised centres. This page explains how the two approaches differ and what they are used for today.
The comparison at a glance
| Feature | Gene therapy | Cell therapy |
|---|---|---|
| Basic idea | Add, switch off or correct genetic information in cells | Living cells take over a task in the body, such as defence or tissue replacement |
| What is given? | A gene carrier (usually a disabled virus), gene-editing tools or cells modified in the laboratory | The patient’s own or donor cells, processed, multiplied or specifically modified in the laboratory |
| Where does it act? | Inside the body (in vivo, e.g. liver, retina) or on cells taken out of the body (ex vivo) | Wherever the cells travel or are placed – blood, joint, skin, heart |
| Typical uses | Rare inherited diseases: spinal muscular atrophy, haemophilia, sickle cell disease, inherited retinal disease | Certain blood cancers (CAR-T), cartilage defects, skin replacement after severe burns |
| Duration of effect | Often intended as a one-off treatment; data over decades are still lacking | One-off or repeated depending on the method; cells may persist or be broken down |
| Main risks | Immune reaction to the gene carrier, unintended changes to the genome, strain from preparatory chemotherapy | Rejection of donor cells, infections, with CAR-T e.g. cytokine release syndrome |
| Authorisation in the EU | As a gene therapy medicinal product (ATMP), centrally via the EMA | As a somatic cell therapy or tissue-engineered product (ATMP) |
Where the two overlap
The boundary is not sharp. The best-known example is CAR-T cells: immune cells are taken from the blood, given a new gene in the laboratory so that they recognise cancer cells, and then infused back. They are therefore cells that have been genetically modified, and EU law counts them as gene therapy medicinal products. The same applies to gene-editing treatments for sickle cell disease, in which blood stem cells are modified outside the body.
Conversely, not every treatment with cells is an advanced therapy. A conventional blood stem cell transplant, in which cells are collected but not substantially processed, has been established for decades and does not fall under the ATMP rules.
How can I tell which is meant?
- If the description mentions a “vector”, “AAV” or “gene editing/CRISPR”, it is a gene therapy.
- If cells are collected, processed and returned without changing their genetic material, it is a cell therapy.
- If cells are collected and genetically modified, it is both – legally a gene therapy in the EU.
- Check the authorisation: authorised ATMPs are listed in the EMA medicines database. Treatments offered abroad only for self-payment often have no authorisation.
Frequently asked questions
Is CAR-T a gene therapy or a cell therapy?
Both: they are immune cells given a new gene in the laboratory. In the EU, CAR-T cells are legally classified as gene therapy medicinal products and authorised centrally by the EMA.
Is stem cell therapy a gene therapy?
Not automatically. If stem cells are only collected and transferred, it is a cell or transplant treatment. Only when their genetic material is changed is it called gene therapy.
Does gene therapy change my children’s genes?
No. Authorised gene therapies change only body cells, not egg or sperm cells. Changes to the germline are prohibited in Germany and are not permitted in clinical use in the EU.
Can my GP give gene or cell therapy?
No. These therapies are prepared, given and followed up in specialised centres, because manufacturing and possible side effects require particular experience.
Read more
- Gene therapy and gene editing in 2026: an overview
- Base, prime and epigenetic editing reach the clinic
- Leukaemia and lymphoma – conditions treated with CAR-T cells
- Longevity in 2026: what research on healthy ageing really shows
General information only; it does not replace medical advice. Last updated: November 2026.
Sources
- European Medicines Agency (EMA): Advanced therapy medicinal products – overview. ema.europa.eu
- Regulation (EC) No 1394/2007 on advanced therapy medicinal products. eur-lex.europa.eu
- U.S. Food and Drug Administration (FDA): What is Gene Therapy? fda.gov
- Paul-Ehrlich-Institut: Advanced therapy medicinal products (ATMP). pei.de